Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. CDC. Antibiotic Resistance Threats in the United States, 2019 (U.S. Department of Health and Human Services, CDC 2019); https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
2. Louie, T. J. et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422–431 (2011).
3. Crawford, T., Huesgen, E. & Danziger, L. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am. J. Health Syst. Pharm. 69, 933–943 (2012).
4. Louie, T. J., Emery, J., Krulicki, W., Byrne, B. & Mah, M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53, 261–263 (2009).
5. Lee, Y. J. et al. Protective factors in the intestinal microbiome against Clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplantation. J. Infect. Dis. 215, 1117–1123 (2017).
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献